Clinically Validated Probiotics
Maximising Patient Engagement in Clinical Trials
Beyond Reporting - Safety surveillance analytics for medical devices...
LYMPHOMA TREATMENT AT A CROSSROADS
Electronic Logs - The next phase of execution maturity in pharma
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Takeda Pharmaceutical Company Limited
Chief Medical & Scientific Officer
Scientific progress depends upon collaboration iPS cell technology is at the forefront of pharmaceutical innovation and Takeda strives to bring innovative treatments to patients Both Takeda and CiRA have the common goal of providing patients and healthcare professionals with innovative new treatments
Articles
How Big Data is Transforming Clinical Trials in Asia
Clinical trials are the cornerstone of medical innovation providing the evidence needed to approve new treatments However these trials often encounter significant challenges particularly in Asia where healthcare landscapes are highly diverse Issues such as recruitment delays regulatory hurdles and resource limitations impede progress
Research Insights
New Developments For Antibody-drug Conjugate-based Therapeutic Approaches
Abstract The clinical success of Adcetris brentuximab vedotin and Kadcyla adotrastuzumab emtansine has sparked clinical development of novel ADCs These powerful anticancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues Despite the use of tumorspecific antibodies
Case Studies
Effect Of Cold Spells And Theirmodifiers On Cardiovascular Disease Events: Evidence From A Double Prospective Study
Abstract Cardiovascular disease CVD is the most common cause of death globally remaining a considerable burden both in terms of health and costs As in many countries CVD mortality in the UK exhibits a marked seasonal variation more people die during the winter months DecemberMarch than in other periods of the year and the majority of deaths occur
Techno Trends
Accela - Breakthrough technology to increase laboratory productivity by Thermo Fisher
Thermo Fisher Scientific has introduced two new solvent delivery systemsAccela HPLC and Accela UHPLC These enable rapid method development reduce solvent consumption and consequently enhance laboratory efficiency These Accela systems Force Feedback Control FFC features render accurate and precise gradients under all operating conditions and flexibility to quaternary...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Unleashing the Power of Data, Collaboration, and Innovation in Drug Development
Pooja is a Healthcare & Life Sciences leader at Thoughtworks with over 15 years of experience in technology consulting. Specialising in AI-driven solutions and strategic initiatives that enhance drug discovery and patient care, she has a unique background in both bioinformatics and product management. Passionate about navigating ambiguity and solving customer problems, Pooja’s current focus is on leveraging emerging technologies to accelerate innovation in healthcare and life sciences.
When Orphan Drugs Make All the Difference
Sue Lee has worked for World Courier for 25 years. During this time she has experienced a variety of customer service and operational functions, including the setting up of numerous, multi-national, clinical sites for the transportation of biological samples. She orchestrated the shipping of thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas.
Advanced Nanobots for ‘Programmed’ Biomedical Applications
Assistant Professor, Department of Applied Sciences, Indian Institute of Information Technology
Research Fellow, Department of Applied Sciences, Indian Institute of Information Technology
Significance of Bioinformatics in Precision Oncology
Pravitha Kasu Sivanandan holds an MSc in Bioinformatics from Bharathiyar University, India, and works as a Bioinformatician at MVR Cancer Centre & Research Institute. She specializes in multi-omics data analysis, focusing on stratified healthcare. She focuses on potential of bioinformatics in precision oncology. Pravitha is also an Associate Member of AACR.
Nanoemulsion - A Promising Nanocarrier for Dermal Drug Delivery in Psoriasis
Sindhoor S M is currently working as an Assistant Professor in the Department of Pharmaceutics at Sri Adichunchanagiri College of Pharmacy, Mandya, Karnataka. His areas of specialisation include nanotechnology-based drug delivery system, lipid-based formulations, Topical delivery and gastroretentive in situ gel systems. He has published eight papers based on nanotechnology and lipid-based drug delivery system in peer reviewed indexed journals. Presently he is involved in the development of lipid-based delivery systems.
Marina Koland, is Professor and Head of the Department of Pharmaceutics at the NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangalore. Her area of specialisation in research is mucoadhesive and nanoparticulate drug delivery. She has published 50 research papers in peer reviewed journals, presented papers at 10 National and 3 International Conferences and worked on several Nitte University funded projects. She is currently working on solid lipid nanoparticles and micelles as drug carriers for targeting.
press releasesRead more...
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine
Ferring Pharmaceuticals and Gameto sign agreement for proposed acquisition
Ferring Pharmaceuticals and Gameto today announced that they have signed an agreement for a global transaction under which Ferring would acquire Gameto Completion remains subject to customary and other closing conditions Until closing the companies will continue to operate independently
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of cancer metabolic autoimmune and other major diseases today announced that a New Indication Application for sintilimab in combination with Nolgileuce...
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
The Menarini Group Menarini a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biot...
Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug
Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...
EventsRead more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWSRead more...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
AstraZeneca and Oracle Launch Global AI Collaboration to Optimise Clinical Trials
AstraZeneca and Oracle Health and Life Sciences have launched a global collaboration to use artificial intelligence AI realworld data and cloud technology to improve clinical trial efficiency and patient outcomes The collaboration will combine AstraZenecas expertise in drug development clinical rese...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies
